Corbus Pharmaceuticals Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $86.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-1.81 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-1.23 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | Before market open | – | $-1.25 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-1.90 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | $-1.39 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | – | $-0.78 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-1.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | $-0.90 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | $-0.83 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | Before market open | – | $-1.81 | – |
Press releases
Announcements Corbus Pharmaceuticals filed with the SEC
Connecting Innovation to Purpose Corporate Presentation October 15, 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation September 14, 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation May 26, 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation March 9, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation February 25, 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation January 12, 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation December 11, 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Announces Pricing of Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose Corporate Presentation October 19, 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation February 14, 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports 3 rd Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation November 7, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation November 4, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Strengthens Board of Directors with
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation August 6, 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
SYS6002 (CRB-701) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation June 1, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K